Skip to content

    Recently Viewed


      3D illustration of influenza virus on grey background

      Fighting the flu: 18 pivotal moments in history that have brought us closer to a cure

      When it struck, the 1918 flu pandemic—one of the deadliest outbreaks on record—killed up to 50 million. As flu season begins, we look at how far we’ve come in fighting the viral infection, including promising work being done on a universal vaccine.

      Share Article
      share to
      When most people think of the flu these days, they may consider it more of a temporary inconvenience than a deadly virus. But a century ago, that most certainly wasn’t the case.

      Last year marked the 100th anniversary of the devastating flu pandemic of 1918, which claimed the lives of an estimated 50 million people worldwide.

      Since then the scientific community has made great strides when it comes to helping prevent the spread of the influenza virus, but there is still work to be done: According to the Centers for Disease Control and Prevention (CDC), the flu was responsible for an estimated 38,000 deaths in the United States alone during the 2016-2017 flu season, and an even greater number were hospitalized with the illness.

      We take a look at how far researchers around the globe have come in battling this foe—and explore current research at Johnson & Johnson that has the potential to pave the way for a flu-free world.
      • Johnson & Johnson Hypodermic Needles That Fit a Standard Syringe
        Image courtesy of Johnson & Johnson Archives

        Johnson & Johnson Debuts Mass-Produced Needles and Syringes

        Fifteen years before the deadly 1918 flu pandemic swept the world, Johnson & Johnson recognized that injectable medications and vaccines would become a crucial tool for rapidly delivering treatments into the bloodstream and began selling hypodermic needles that fit a standard syringe (shown at right).

        This was forward-thinking for the time, since most drugs were ingested rather than injected, and injections were an advance over earlier vaccination methods. These tools would soon become critical instruments enabling doctors to administer the influenza vaccine.
      • Newspaper Image of The Johnson & Johnson Epidemic Mask, Which Was Worn to Prevent the Spread of the Flu
        Image courtesy of Johnson & Johnson Archives

        The Spanish Flu Pandemic Strikes

        This flu pandemic was the deadliest in modern history, infecting an estimated 500 million people worldwide and killing up to 50 million—an even more devastating death toll than World War I. More than 25% of the U.S. population became sick.

        Johnson & Johnson played a key role in helping to prevent the spread of the virus by introducing the epidemic mask, made from sterile gauze. It proved so effective that it was also used in later outbreaks.
      • A Microscopic Image of the Human Influenza Virus

        Scientists Isolate the Human Influenza Virus

        Influenza vaccine development—a high priority for the U.S. military following the deaths of approximately one in every 67 soldiers from the flu during the 1918-1919 pandemic—took a major step forward when researchers at the UK’s Medical Research Council were able to isolate the virus (shown at right) from humans.

        Virologist Patrick Laidlaw and his team were working with ferrets to develop a distemper vaccine when the animals caught the flu from Wilson Smith, one of the scientists in the laboratory. The team dubbed it the “W.S.” virus, and their discovery made it possible to develop a vaccine.
      • Doctor preparing a flu shot

        The First Flu Vaccine Is Introduced

        Soviet scientist A.A. Smorodintseff made the first attempt to vaccinate people with a live influenza vaccine. Following in the footsteps of Louis Pasteur—who had made the first known attempt to vaccinate humans with a live, attenuated viral strain of rabies in 1885—Smorodintseff passed the live flu virus about 30 times in eggs, so it lost its virulence. He reported that those injected with the modified virus developed a slight fever but were protected against reinfection.

        The attenuated virus was then used for mass production of a vaccine that was largely administered to factory workers, who were susceptible to outbreaks due to close working conditions.
      • Schoolchildren Wait in Line for Immunization Shots at a Child Health Station in New York City, Circa 1946.
        Image courtesy of Library of Congress

        The First U.S. Influenza Vaccine Is Approved

        This whole-virus, inactivated influenza A and B vaccine was first tested in military recruits and college students before it received approval for military use in the United States. A year later, it was approved for civilian use, as well. At right, schoolchildren wait in line for immunization shots at a child health station in New York City, circa 1946.

        There are four types of influenza virus—A, B, C and D—but only the A and B types are thought to cause viral epidemics in humans, according to the CDC.
      • JELCO® Disposable Syringes
        Image courtesy of Johnson & Johnson Archives

        Disposable Hypodermic Needles and Syringes Are Invented

        Disposable syringes and needles were introduced in the 1950s, and were mass-produced starting in 1954.

        JELCO®, then part of the Johnson & Johnson family of companies, introduced a new line of one-time use hypodermic needles and syringes in 1964 that helped prevent cross-contamination between patients during the administration of injected medicines and vaccines, such as the influenza vaccine.
      • A Microscopic Image of H2N2, a Mixed Strain Many Scientists Believe Originated From a Combination of Bird and Human Flu Viruses

        The Asian Flu Pandemic Hits

        This was the second major influenza pandemic of the 20th century, killing about 2 million worldwide, including almost 70,000 in the United States. It was caused by a virus known as influenza A subtype H2N2 (shown at right), a mixed strain many scientists believe originated from a combination of bird (the Spanish flu pandemic was caused by a virus that developed from an avian source) and human flu viruses.

        Influenza strains are characterized by two proteins on the outer surface of the virus: hemagglutinin and neuraminidase (represented by H and N, respectively). There are 14 versions of the H protein and nine versions of the N protein, according to the American Council on Science and Health.

        The virus was first identified in Guizhou, China, in 1956. It spread to Singapore by February 1957, Hong Kong by that April and the U.S. by June. A vaccine was developed to contain the outbreak in 1957, but the strain would later evolve via antigenic shift into H3N2, causing a milder pandemic between 1968 and 1969.
      • Woman wearing reusable mask

        The Hong Kong Flu Pandemic Strikes

        The third major flu pandemic of the century, the Hong Kong pandemic (the first known outbreak of the H3N2 strain), killed about 1 million people worldwide, accounting for 34,000 deaths in the United States.

        Compared to the first two pandemics of the century, this one yielded a lower death rate, with a case-to-fatality ratio below 0.5%.

        Possible reasons for this include the fact that there was some immunity against the N2 virus amongst those who had survived the Asian flu pandemic; the outbreak struck around the winter school holidays, limiting its spread in schools; improved medical care better supported the very ill; and antibiotics were available to help ward off secondary bacterial infections.
      • Child standing in school courtyard wearing a disposable mask with a backpack on her back

        The Russian Flu Pandemic Spreads

        Technically considered the fourth pandemic of the 20th century (there is no accurate death count on record), this outbreak—which started in China and Russia but eventually spread worldwide—mainly affected people under the age of 25.

        Researchers would later theorize that an older H1N1 virus had mysteriously resurfaced, only impacting younger people who had never been exposed to it.
      • Nurse administering shot into patient's arm

        Researchers Unveil the First Trivalent Vaccine

        The first trivalent (three-component), egg-cultured flu vaccine was created, containing two influenza A strains (H1N1 and H3N2) and one influenza B strain, which were the most common strains in circulation at the time.

        This was the first time a single vaccine was able to protect against three different strains of the flu, and this type of vaccine is still given today.

        Currently, the World Health Organization recommends the composition of influenza vaccines each year, based on the results of its global influenza surveillance, which helps the organization predict the strains most likely to circulate in the coming flu season.
      • Sick man wearing scarf and blanket sitting on couch with a cup of tea

        Two New Ways to Help Ease Flu Symptoms Become Available

        Two antivirals, oseltamivir phosphate and zanamivir, were approved by the Food and Drug Administration (FDA) for the treatment of influenza A and B. Both medications were shown to reduce such flu symptoms as fever, chills, muscle aches, sore throat and a runny or stuffy nose.

        Prior to their approval, people suffering from the flu had to rely on over-the-counter drugs to help relieve their symptoms. Both of these medications require a physician’s prescription and are effective in patients who’ve been symptomatic for no more than 48 hours.
      • Female doctor talking to little girl and mom

        A Nasal Vaccine Is Approved

        The first nasally administered influenza vaccine was licensed for healthy, nonpregnant people between the ages of 5 and 49. In 2007, it was also approved for younger kids between the ages of 2 and 5. This type of vaccine is helpful for those who are unwilling or unable to receive the vaccine via injection.
      • A group of chickens in a warehouse

        The First Avian Influenza Vaccine Is Approved

        The FDA approved the first U.S. vaccine for humans against the avian influenza virus H5N1. Although human cases of avian influenza occur only occasionally, the mortality rate when people do become infected is about 60%, according to a study published in Pathogens and Global Health.
      • Two scientists in full PPE working in a lab with beakers and microscopes

        Work Begins on a Universal Flu Vaccine

        Johnson & Johnson announced that it will begin work on the development of a new universal flu vaccine designed to fight all types of the virus, using molecules called mini-HA antigens that contain parts of the flu virus that appear within a wide variety of viruses. The goal: provide longer-lasting protection than the regular seasonal flu shot.

        The catalyst for this was a 2008 discovery by Crucell (now part of the Johnson & Johnson family of companies) that human antibody CR6261 could protect against a broad spectrum of influenza viruses. It was then that researchers realized humans are capable of producing antibodies against the part of the influenza virus that doesn’t change—an idea that was not accepted before this time.

        “Current flu vaccines have to be changed year to year, and even then, they only reduce the risk of developing the flu by 40 to 60%,” explains Ted Kwaks, Ph.D., Director for Project Management and External Innovation, Viral Vaccines Discovery, Janssen Pharmaceuticals, part of the Johnson & Johnson family of companies. “The theory is that, ultimately, we’ll put these antigens into a vaccine that will provide protection against virtually all flu strains.”
      • A close-up of a group of pigs in a barn

        The Swine Flu Pandemic Hits

        The H1N1 (swine flu) pandemic—caused by the same strain of virus responsible for the 1918 pandemic—originated in Mexico and spread rapidly, killing up to a half-million people worldwide. There were about 60 million reported cases of infection, with more than 274,000 hospitalizations and upward of 12,000 deaths in the United States.

        The virus isolated from patients in the U.S. was made up of genetic elements from four different flu viruses: North American swine influenza, North American avian influenza, human influenza and a swine influenza virus typically found in Asia and Europe. One characteristic of the swine flu was that it did not disproportionately affect those over the age of 60, like most other strains, since those who contracted the flu before 1957 seemed to have some immunity to H1N1.

        Although the flu is viral, the H1N1 strain damaged the lungs of its victims, leaving them susceptible to such secondary bacterial infections as pneumonia. Thankfully, antibiotics were readily available in 2009, which greatly reduced these complications.
      • A line of vaccine bottles with a syringe in the first bottle

        The FDA Approves the First Quadrivalent Vaccine

        The first quadrivalent vaccine, which fights against four strains of the flu—two influenza A and two influenza B lineage strains—was approved by the FDA.

        The addition of a second influenza B strain to the vaccine aimed to provide broader protection against circulating flu viruses. Although influenza B viruses have never been reported to be responsible for a pandemic, they have been reported to cause localized epidemics, and they have been the most prevalent viruses during certain flu seasons.
      • A child laying in a hospital bed with an IV in his hand

        U.S. Patients Have a New Option for Helping to Relieve Flu Symptoms

        The FDA approved the antiviral peramivir for the relief of flu symptoms, including cough, sore throat, nasal congestion, headache, feverishness, muscle aches and fatigue.

        Unlike other drugs of its kind, it’s taken intravenously and only requires one dose. The medication is available to patients admitted to the Emergency Department who may not be candidates for oral treatment, including those who are severely dehydrated, have swallowing issues or who do not have a fully functioning gastrointestinal tract.
      • A patient in a hospital gown holding hands with a doctor

        Johnson & Johnson Partners With the U.S. Department of Health and Human Services

        Johnson & Johnson announced a collaboration with the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response to develop a comprehensive portfolio of therapeutics and vaccines to protect communities in the event of an influenza pandemic. The hope is to help prevent the more than 1 billion cases of influenza globally each year that result in 5 million cases of severe illness and up to a half-million deaths.

      Help Alana’s Foundation Help People in Need

      Consider donating to the organization, which distributes flu vaccines to those who otherwise couldn’t afford them.

      More from Johnson & Johnson

      Health & wellness
      3D human heart anatomy illustrations

      Do you know what heart failure is? (Hint: It’s probably not what you think)

      For American Heart Month, learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.
      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      Latest news
       Biomedical scientist Robert Langer headshot

      Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research

      Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.